Doctor-led aesthetics in Sutton Coldfield
MDr MaryamAesthetics

Polynucleotides

Why can polynucleotide injections sting? What does the 2026 study show?

A small split-face trial suggests that one adjusted polynucleotide formulation may reduce injection pain, but comfort varies and the result cannot be applied to every product or treatment area.

5 minute read

Discomfort is part of the treatment decision

Polynucleotide treatment usually involves multiple small injections rather than a single injection point. Patients may describe a sharp sting, pressure or burning as the product enters the skin. The experience varies with the area treated, product formulation, injection depth and volume, technique, skin sensitivity and individual pain threshold.

Pain should not be dismissed as something a patient must simply tolerate. It can affect whether somebody feels able to complete a procedure or return for further sessions. Equally, a treatment should not be described as painless: topical numbing or other comfort measures may reduce sensation, but they cannot guarantee no discomfort.

What did the 2026 trial compare?

A randomised, patient-blinded, split-face study enrolled 15 adults seeking improvement in lines around the eyes. Each participant received a standard polynucleotide formulation on one side and a test formulation with adjusted pH and ionic conditions on the other. Four sessions were given at two-week intervals by the same investigator.

Participants wore eye masks and rated pain on a ten-point visual scale after treatment. Because each person received both formulations, the design reduced differences caused by individual pain tolerance. Researchers also recorded local reactions and assessed crow’s-feet appearance and patient-reported improvement for up to 12 weeks.

The test formulation hurt less on average

Average pain scores were lower with the adjusted formulation: 3.39 compared with 5.01 for the standard formulation. Across 60 paired procedures, the adjusted side was rated less painful in 48. Redness and temporary raised injection points were also recorded less often, while bruising did not differ significantly between sides.

Both sides improved on the study’s wrinkle scales, with no statistically significant difference between formulations. This suggests that the formulation change may have improved comfort without an obvious reduction in the measured short-term result. It does not show that lower pain makes polynucleotides more effective or that every patient will prefer the same product.

Why the evidence needs restraint

Only 15 people took part at one centre, and all treatment was around the eyes. Patients were blinded, but the injector could identify the devices. The study was supported by the manufacturer of the test formulation, and the small sample was not capable of detecting uncommon complications or subtle differences in effectiveness.

The comparison was between two specific formulations delivered with the same needle and protocol. It cannot establish that all pH-adjusted products hurt less, predict discomfort on the cheeks, neck or lips, or justify altering a product in clinic. Products should be used according to their instructions; formulation-specific findings should not become a general promise.

Comfort planning and expected downtime

A consultation should ask about previous injection experiences, fainting, anxiety, allergies and sensitivity to numbing preparations. The clinician can explain the planned technique, agree a pause signal and discuss appropriate comfort measures for the exact product and area. Feeling informed and able to stop is an important part of consent.

Temporary redness, tenderness, swelling, small raised points, itching, pinpoint bleeding or bruising may follow treatment. In the trial, recorded reactions were local and no systemic effects were observed, but the sample was too small to define overall safety. Increasing pain, spreading heat or redness, discharge, fever, unusual skin colour or worsening swelling needs prompt clinical advice.

Suitability comes before comfort

A less painful formulation would not make treatment suitable for everyone. The exact product, treatment goal, skin condition, medical history, medicines, allergies, pregnancy or breastfeeding, previous injectable reactions and other planned procedures all require review. Active infection, inflammation or damaged skin may mean postponing treatment.

A 2026 systematic review found only seven randomised PN and PDRN trials involving 183 participants across different uses. It reported generally mild local reactions but emphasised small studies, mixed protocols and limited follow-up. GMC guidance requires clear discussion of evidence, risks, alternatives and follow-up, including the option not to proceed. Comfort matters, but it is only one part of a balanced decision.

← Back to the journal

Personalised medical assessment

Questions about treatment?

Book a consultation to discuss your concerns, health and treatment options without pressure.

Free consultation – a £1 booking fee secures your appointment